Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

US6933311B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Chih-Hung Lee · Vernon Hills, US
• Erol K. Bayburt · Gurnee, US
• Stanley DiDomenico · Richmond, US
• Irene Drizin · Wadsworth, US
• Arthur Gomtsyan · Vernon Hills, US
• John R. Koenig · Chicago, US
• Richard J. Perner · Gurnee, US
• Robert G. Schmidt · Waukegan, US
• Sean Colm Turner · Ludwigshafen, DE
• Tammie White · Gurnee, US
• Guo Zhu Zheng · Lexington, US

Key dates

• Filing date: Aug 5, 2003
• Grant date: Aug 23, 2005
• Expiry date: Aug 5, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.